Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

被引:73
作者
Eap, CB
Lessard, E
Baumann, P
Brawand-Amey, M
Yessine, MA
O'Hara, G
Turgeon, J
机构
[1] Hop Cery, DUPA, Unite Biochim & Psychopharmacol, CH-1008 Lausanne, Switzerland
[2] Univ Laval, Fac Pharm, Ste Foy, PQ G1K 7P4, Canada
[3] Univ Laval, Fac Med, Ste Foy, PQ G1K 7P4, Canada
[4] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
来源
PHARMACOGENETICS | 2003年 / 13卷 / 01期
关键词
venlafaxine; CYP2D6; CYP3A4; enantiomer; PLASMA-CONCENTRATIONS; THERAPEUTIC RESPONSE; ENANTIOMERS; METHADONE; PHARMACOKINETICS; MIANSERIN; GENOTYPE;
D O I
10.1097/00008571-200301000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
CYP2D6 is involved in the O-demethylation metabolic pathway of venlafaxine in humans. In this study, we investigated whether this isozyme is stereoselective. Plasma samples from seven CYP2D6 extensive metabolizers (EMs) and five CYP2D6 poor metabolizers (PMs), collected during a period without and with coadministration of quinidine, were analysed. Subjects were administered venlafaxine hydrochloride 18.75 mg orally every 12 h for 48 h on two occasions (1 week apart); once alone and once during the concomitant administration of quinidine sulphate every 12 h. Blood and urine samples were collected under steady-state conditions over one dosing interval (112 h). The present results show that, although CYP2D6 catalyses the O-demethylation of both enantiomers of venlafaxine, it displays a marked stereoselectivity towards the O-enantiomer. The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) 1/h versus 20 (16-24) 1/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) 1/h versus 37 (21-44) 1/h, P < 0.05]. In EMs, quinidine decreased (R)- and (S)-venlafaxine oral clearance by 12-fold (P < 0.05) and four-fold (P < 0.05), respectively. In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) 1/h for venlafaxine alone versus 5 (0.6-7) 1/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (11-7) 1/h for venlafaxine alone versus 3 (0.4-6) 1/h for venlafaxine + quinidine]. The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) 1/h down to 1 (0.1-3) 1/h, P < 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) 1/h versus 7 (1-19) 1/h, P< 0.05]. In PMs, coadministration of quinidine did not significantly change oral clearance and partial metabolic clearance of (R)- and (S)-venlafaxine to its various metabolites. In contrast, data obtained on the partial metabolic clearance of (R)- and (S)-venlafaxine to N-demethylated metabolites, a reaction which is mediated by CYP3A4, suggest a lack of stereoselectivity of this enzyme.
引用
收藏
页码:39 / 47
页数:9
相关论文
共 17 条
[1]   Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers [J].
Begré, S ;
von Bardeleben, U ;
Ladewig, D ;
Jaquet-Rochat, S ;
Cosendai-Savary, L ;
Golay, KP ;
Kosel, M ;
Baumann, P ;
Eap, CB .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (02) :211-215
[2]   STEREOSELECTIVE DISPOSITION OF MIANSERIN IS RELATED TO DEBRISOQUIN HYDROXYLATION POLYMORPHISM [J].
DAHL, ML ;
TYBRING, G ;
ELWIN, CE ;
ALM, C ;
ANDREASSON, K ;
GYLLENPALM, M ;
BERTILSSON, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :176-183
[3]   Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: A case report [J].
Eap, CB ;
Bertel-Laubscher, R ;
Zullino, D ;
Amey, M ;
Baumann, P .
PHARMACOPSYCHIATRY, 2000, 33 (03) :112-115
[4]   Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone [J].
Eap, CB ;
Bertschy, G ;
Powell, K ;
Baumann, P .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (02) :113-117
[5]   Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites [J].
Eap, CB ;
Yasui, N ;
Kaneko, S ;
Baumann, P ;
Powell, K ;
Otani, K .
THERAPEUTIC DRUG MONITORING, 1999, 21 (02) :166-170
[6]   Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment [J].
Eap, CB ;
Bourquin, M ;
Martin, JL ;
Spagnoli, J ;
Livoti, S ;
Powell, K ;
Baumann, P ;
Déglon, JJ .
DRUG AND ALCOHOL DEPENDENCE, 2000, 61 (01) :47-54
[7]   Methadone N-demethylation in human liver microsomes:: lack of stereoselectivity and involvement of CYP3A4 [J].
Foster, DJR ;
Somogyi, AA ;
Bochner, F .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) :403-412
[8]   Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers [J].
Fukuda, T ;
Yamamoto, I ;
Nishida, Y ;
Zhou, Q ;
Ohno, M ;
Takada, K ;
Azuma, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (04) :450-453
[9]   The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population [J].
Fukuda, T ;
Nishida, Y ;
Zhou, Q ;
Yamamoto, I ;
Kondo, S ;
Azuma, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (02) :175-180
[10]   Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability [J].
Gex-Fabry, M ;
Rudaz, S ;
Balant-Gorgia, AE ;
Brachet, A ;
Veuthey, JL ;
Balant, LP ;
Bertschy, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (05) :323-331